Share this article
SAN DIEGO, April 10, 2021 /PRNewswire/
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced observations from its Expanded Access Program (EAP) of onvansertib in KRAS-mutated metastatic colorectal cancer (mCRC), featured in a virtual oral poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021.
Cardiff Oncology s EAP has enrolled participants who failed or progressed on multiple lines of standard-of-care treatment and uses the same combination regimen (onvansertib 15 mg/m
Boundless Bio Presents Data on the Role of Extrachromosomal DNA (ecDNA) in Mediating Resistance to Targeted Therapies at the American Association for Cancer Research (AACR) Annual Meeting 2021 tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.
Share:
Insights into Inhibigen biology may yield new therapeutic targets to address immunotherapy resistance
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today presented preclinical data that offers new insights into Inhibigen™-associated responses and continues to underscore the detrimental impact of their inclusion in cancer immunotherapies at the American Association for Cancer Research (AACR) Annual Meeting 2021 from April 10-15. The findings – powered by Genocea s proprietary ATLAS™ platform – further validate previous research presented at SITC 2020 and published in
Cancer Discovery, together revealing that the presence of an Inhibigen (antigen uniquely identifiable by ATLAS as dampening anti-tumor immune responses) in an otherwise protective immunotherapy can completely reverse the therapy s intended anti-tumor responses.
(0)
Data support potential of DARPin® CD3 T-cell engager candidate for improved safety window while limiting tumor escape
New data show that the FAP x CD40 product candidate, MP0317, led to a localized macrophage repolarization and reversion of T-cell suppression. Clinical trials expected to initiate in the second half of 2021
Effector control technologies give new potential for enhancing current and future immunotherapies while reducing toxicities
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / April 10, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the presentation of four posters highlighting research across its immuno-oncology programs at the American Association for Cancer Research (AACR) virtual Annual Meeting. The preclinical data shared include results from the Company s acute myeloid leukemia (AML) CD3 T-cell engager program, new data fro
MEI Pharma Reports Preclinical Data Demonstrating Ability of Voruciclib to Regulate MYC and Synergize with KRAS Inhibitors in KRAS Mutant Cancers
Data Featured in Poster at American Association for Cancer Research Annual Meeting 2021
Investor and Analyst Video Webcast Event on Tuesday, April 13, 2021 at 8:00 AM Eastern Time
News provided by
Share this article
Share this article
SAN DIEGO, April 10, 2021 /PRNewswire/ MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced preclinical data demonstrating that voruciclib, an orally administered cyclin-dependent kinase (CDK) inhibitor that is potent against CDK9, has single agent activity against multiple KRAS mutant cancer cell lines and synergistically inhibits growth of KRAS mutant cancers in combination with KRAS inhibitors. The research is featured as an E-Poster Session presentation titled, Voruciclib, a CDK9 inhibitor, downregulates MYC and inhibi